<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p36" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_36{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_36{left:341px;bottom:30px;}
#t3_36{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_36{left:377px;bottom:30px;}
#t5_36{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_36{left:540px;bottom:30px;}
#t7_36{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_36{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_36{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_36{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_36{left:285px;bottom:827px;letter-spacing:-0.26px;}
#tc_36{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_36{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_36{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_36{left:1108px;bottom:28px;letter-spacing:0.29px;}
#tg_36{left:36px;bottom:165px;}
#th_36{left:42px;bottom:159px;letter-spacing:0.12px;word-spacing:0.01px;}
#ti_36{left:759px;bottom:159px;letter-spacing:0.13px;}
#tj_36{left:833px;bottom:159px;letter-spacing:0.08px;}
#tk_36{left:36px;bottom:149px;}
#tl_36{left:42px;bottom:143px;letter-spacing:0.13px;word-spacing:-0.06px;}
#tm_36{left:327px;bottom:143px;}
#tn_36{left:36px;bottom:132px;}
#to_36{left:46px;bottom:126px;letter-spacing:0.14px;word-spacing:-0.06px;}
#tp_36{left:440px;bottom:126px;}
#tq_36{left:36px;bottom:115px;}
#tr_36{left:47px;bottom:109px;letter-spacing:0.07px;word-spacing:0.06px;}
#ts_36{left:36px;bottom:778px;letter-spacing:0.48px;}
#tt_36{left:36px;bottom:760px;letter-spacing:0.25px;}
#tu_36{left:469px;bottom:778px;letter-spacing:0.32px;word-spacing:-0.31px;}
#tv_36{left:787px;bottom:786px;}
#tw_36{left:984px;bottom:775px;letter-spacing:0.34px;}
#tx_36{left:36px;bottom:535px;letter-spacing:-0.11px;}
#ty_36{left:468px;bottom:726px;letter-spacing:-0.1px;}
#tz_36{left:663px;bottom:733px;}
#t10_36{left:676px;bottom:726px;letter-spacing:-0.08px;}
#t11_36{left:468px;bottom:707px;letter-spacing:-0.1px;}
#t12_36{left:588px;bottom:715px;}
#t13_36{left:596px;bottom:707px;letter-spacing:-0.08px;}
#t14_36{left:468px;bottom:689px;letter-spacing:-0.06px;}
#t15_36{left:468px;bottom:671px;letter-spacing:-0.09px;}
#t16_36{left:673px;bottom:678px;}
#t17_36{left:681px;bottom:671px;letter-spacing:-0.09px;}
#t18_36{left:468px;bottom:652px;letter-spacing:-0.1px;}
#t19_36{left:468px;bottom:634px;letter-spacing:-0.1px;}
#t1a_36{left:607px;bottom:642px;}
#t1b_36{left:620px;bottom:634px;letter-spacing:-0.09px;}
#t1c_36{left:468px;bottom:542px;letter-spacing:-0.09px;}
#t1d_36{left:468px;bottom:523px;letter-spacing:-0.1px;}
#t1e_36{left:529px;bottom:531px;}
#t1f_36{left:599px;bottom:569px;letter-spacing:-0.09px;}
#t1g_36{left:599px;bottom:551px;letter-spacing:-0.13px;}
#t1h_36{left:622px;bottom:558px;}
#t1i_36{left:630px;bottom:551px;letter-spacing:-0.1px;}
#t1j_36{left:871px;bottom:558px;}
#t1k_36{left:599px;bottom:533px;letter-spacing:-0.09px;}
#t1l_36{left:599px;bottom:514px;letter-spacing:-0.09px;}
#t1m_36{left:599px;bottom:496px;letter-spacing:-0.1px;}
#t1n_36{left:599px;bottom:478px;letter-spacing:-0.1px;}
#t1o_36{left:824px;bottom:485px;}
#t1p_36{left:984px;bottom:604px;letter-spacing:-0.1px;}
#t1q_36{left:984px;bottom:585px;letter-spacing:-0.09px;}
#t1r_36{left:213px;bottom:689px;letter-spacing:-0.09px;}
#t1s_36{left:213px;bottom:671px;letter-spacing:-0.09px;}
#t1t_36{left:213px;bottom:542px;letter-spacing:-0.11px;word-spacing:0.01px;}
#t1u_36{left:213px;bottom:523px;letter-spacing:-0.1px;}
#t1v_36{left:213px;bottom:405px;letter-spacing:-0.11px;word-spacing:0.01px;}
#t1w_36{left:213px;bottom:387px;letter-spacing:-0.1px;}
#t1x_36{left:1004px;bottom:500px;letter-spacing:-0.09px;}
#t1y_36{left:1004px;bottom:481px;letter-spacing:-0.08px;}
#t1z_36{left:1004px;bottom:463px;letter-spacing:-0.1px;}
#t20_36{left:1004px;bottom:445px;letter-spacing:-0.25px;}
#t21_36{left:468px;bottom:396px;letter-spacing:-0.1px;}
#t22_36{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_36{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_36{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_36{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_36{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_36{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_36{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_36{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_36{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s8_36{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s9_36{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sa_36{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sb_36{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sc_36{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts36" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg36Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg36" style="-webkit-user-select: none;"><object width="1210" height="935" data="36/36.svg" type="image/svg+xml" id="pdf36" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_36" class="t s0_36">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_36" class="t s1_36">® </span>
<span id="t3_36" class="t s0_36">(NCCN </span>
<span id="t4_36" class="t s1_36">® </span>
<span id="t5_36" class="t s0_36">), All rights reserved. NCCN Guidelines </span>
<span id="t6_36" class="t s1_36">® </span>
<span id="t7_36" class="t s0_36">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_36" class="t s2_36">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_36" class="t s2_36">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_36" class="t s3_36">NCCN Guidelines Version 4.2024 </span>
<span id="tb_36" class="t s3_36">Cancer of the Nasopharynx </span>
<span id="tc_36" class="t s4_36">NCCN Guidelines Index </span>
<span id="td_36" class="t s4_36">Table of Contents </span>
<span id="te_36" class="t s4_36">Discussion </span>
<span id="tf_36" class="t s5_36">NASO-3 </span>
<span id="tg_36" class="t s6_36">i </span>
<span id="th_36" class="t s7_36">The recommendations are based on clinical trial data for those with EBV-associated nasopharynx cancer (</span><span id="ti_36" class="t s8_36">Discussion</span><span id="tj_36" class="t s7_36">). </span>
<span id="tk_36" class="t s6_36">j </span>
<span id="tl_36" class="t s8_36">Principles of Radiation Therapy (NASO-A)</span><span id="tm_36" class="t s7_36">. </span>
<span id="tn_36" class="t s6_36">k </span>
<span id="to_36" class="t s8_36">Systemic Therapy for Nasopharyngeal Cancers (NASO-B)</span><span id="tp_36" class="t s7_36">. </span>
<span id="tq_36" class="t s6_36">n </span>
<span id="tr_36" class="t s7_36">You R, et al. JAMA Oncol 2020;6:1345-1352. </span>
<span id="ts_36" class="t s5_36">CLINICAL </span>
<span id="tt_36" class="t s5_36">STAGING </span>
<span id="tu_36" class="t s5_36">TREATMENT OF PRIMARY AND NECK </span>
<span id="tv_36" class="t s9_36">i </span>
<span id="tw_36" class="t s5_36">FOLLOW-UP </span>
<span id="tx_36" class="t s5_36">T1–4,N0–3,M1 </span>
<span id="ty_36" class="t s5_36">Induction chemotherapy </span>
<span id="tz_36" class="t s9_36">k </span>
<span id="t10_36" class="t s5_36">(if PS 0–1) </span>
<span id="t11_36" class="t s5_36">followed by RT </span>
<span id="t12_36" class="t s9_36">j </span>
<span id="t13_36" class="t s5_36">or cisplatin/RT </span>
<span id="t14_36" class="t s5_36">or </span>
<span id="t15_36" class="t s5_36">Concurrent cisplatin + RT </span>
<span id="t16_36" class="t s9_36">j </span>
<span id="t17_36" class="t s5_36">(if PS 0–1) </span>
<span id="t18_36" class="t s5_36">or </span>
<span id="t19_36" class="t s5_36">Systemic therapy </span>
<span id="t1a_36" class="t s9_36">k </span>
<span id="t1b_36" class="t s5_36">(if PS 0–2) </span>
<span id="t1c_36" class="t s5_36">Systemic </span>
<span id="t1d_36" class="t s5_36">therapy </span>
<span id="t1e_36" class="t s9_36">k </span>
<span id="t1f_36" class="t sa_36" data-mappings='[[29,"fi"]]'>If CR or near CR, consider deﬁnitive </span>
<span id="t1g_36" class="t s5_36">RT </span>
<span id="t1h_36" class="t s9_36">j </span>
<span id="t1i_36" class="t s5_36">to primary and regional nodes </span>
<span id="t1j_36" class="t s9_36">n </span>
<span id="t1k_36" class="t s5_36">(preferred) and to oligometastases as </span>
<span id="t1l_36" class="t s5_36">indicated </span>
<span id="t1m_36" class="t s5_36">or </span>
<span id="t1n_36" class="t s5_36">Continued systemic therapy </span>
<span id="t1o_36" class="t s9_36">k </span>
<span id="t1p_36" class="t s5_36">Follow-up </span>
<span id="t1q_36" class="t sb_36">(FOLL-A, 1 of 2) </span>
<span id="t1r_36" class="t s5_36">Oligometastatic </span>
<span id="t1s_36" class="t s5_36">disease </span>
<span id="t1t_36" class="t s5_36">Widely metastatic and </span>
<span id="t1u_36" class="t s5_36">Good PS (0–2) </span>
<span id="t1v_36" class="t s5_36">Widely metastatic </span>
<span id="t1w_36" class="t s5_36">and Poor PS (3–4) </span>
<span id="t1x_36" class="t s5_36">Recurrent or </span>
<span id="t1y_36" class="t s5_36">persistent </span>
<span id="t1z_36" class="t s5_36">disease </span>
<span id="t20_36" class="t sb_36">(ADV-3) </span>
<span id="t21_36" class="t s5_36">Best supportive care </span>
<span id="t22_36" class="t sc_36">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
